Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Levin PA, Nguyen H, Wittbrodt ET, Kim SC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	antidiabetic drugs randomized controlled trials retrospective type 2 diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6280559cff2643bda0e3000148b48e08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6280559cff2643bda0e3000148b48e08
record_format	dspace
spelling	oai:doaj.org-article:6280559cff2643bda0e3000148b48e082021-12-02T03:36:41ZGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research1178-7007https://doaj.org/article/6280559cff2643bda0e3000148b48e082017-04-01T00:00:00Zhttps://www.dovepress.com/glucagon-like-peptide-1-receptor-agonists-a-systematic-review-of-compa-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety.Objective: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed.Methods: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D.Results: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings.Conclusion: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D. Keywords: antidiabetic drugs, randomized controlled trials, retrospective, type 2 diabetesLevin PANguyen HWittbrodt ETKim SCDove Medical Pressarticleantidiabetic drugsrandomized controlled trialsretrospectivetype 2 diabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 123-139 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	antidiabetic drugs randomized controlled trials retrospective type 2 diabetes Specialties of internal medicine RC581-951
spellingShingle	antidiabetic drugs randomized controlled trials retrospective type 2 diabetes Specialties of internal medicine RC581-951 Levin PA Nguyen H Wittbrodt ET Kim SC Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
description	Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety.Objective: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed.Methods: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D.Results: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings.Conclusion: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D. Keywords: antidiabetic drugs, randomized controlled trials, retrospective, type 2 diabetes
format	article
author	Levin PA Nguyen H Wittbrodt ET Kim SC
author_facet	Levin PA Nguyen H Wittbrodt ET Kim SC
author_sort	Levin PA
title	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
title_short	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
title_full	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
title_fullStr	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
title_full_unstemmed	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
title_sort	glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/6280559cff2643bda0e3000148b48e08
work_keys_str_mv	AT levinpa glucagonlikepeptide1receptoragonistsasystematicreviewofcomparativeeffectivenessresearch AT nguyenh glucagonlikepeptide1receptoragonistsasystematicreviewofcomparativeeffectivenessresearch AT wittbrodtet glucagonlikepeptide1receptoragonistsasystematicreviewofcomparativeeffectivenessresearch AT kimsc glucagonlikepeptide1receptoragonistsasystematicreviewofcomparativeeffectivenessresearch
_version_	1718401667042377728

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Ejemplares similares